Six weeks after Rwanda-backed rebels captured the eastern Congolese cities of Goma and Bukavu, the region is facing a setback ...

Tanzania has confirmed its first two cases of mpox, the health ministry said Monday, the first time the virus has been ...

Tecovirimat failed to reduce clade II mpox lesions, pain or viral clearance among participants in a study of the antiviral ...

The mpox virus is currently rampaging through the Democratic Republic of Congo, with 2,000 cases since the start of the year ...

By day 29 following study entry ... receiving tecovirimat and by 3.1 points among those receiving the placebo. Participants' ...

Nurses are administering medicine to Mpox patients at a tent in Kabare, Democratic Republic of the Congo, as the area ...

A NIH-led trial found tecovirimat ineffective in reducing mpox lesion healing time or pain relief. The study was halted in 2024, with findings presented at CROI 2025.

Patients with uncontrolled HIV infection, particularly Black individuals, exhibited increased risk for severe mpox (formerly monkeypox ... risks for the primary composite (OR, 4.7; 95% CI, 1.6-14.0), ...

The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox ...

NIH-sponsored trial data offers further evidence to help inform mpox treatment decisions.